Recently, S&P Global Corporate Sustainability Assessment (CSA) has been releasing the results of 2023 Environmental, Social and Governance (ESG) scores. Sino Biopharm (HK.1177) has achieved a second consecutive year of improved ratings. This year, the Group's rating steadily improved to 55 points, up 10 points from the previous year, and ranked in the top 9% globally for the second consecutive year.

The S&P Global Corporate Sustainability Assessment is one of the world's largest annual assessments of corporate sustainability practices, which comprehensively reflects the level of ESG management and disclosure of companies through quantitative scoring of companies' ESG management and performance, and is an important basis for investment decisions and data analysis by global investors. 2023, approximately 350 companies in the pharmaceutical industry around the world were invited to participate in the assessment. For two consecutive years, the company has outperformed 91% of its global peers, representing the organization's high recognition of Sino Biopharm's sustainable development practices.

In terms of corporate governance, Sino Biopharm continues to enhance the professionalism, independence and diversity of its board of directors, and safeguard the stable operation of the enterprise with high-quality corporate governance. In recent years, Sino Biopharm has persisted in internationalization and innovation, and continuously increased its investment in independent research and development. Currently, the Group has entered the harvesting period of innovation results. in 2022, the net revenue of innovative drugs will reach RMB 6.75 billion, a year-on-year growth of 20%. In the next three years, the Group will have nearly 10 innovative drugs on the market, injecting strong momentum for long-term sustainable development. In the area of risk management, the Group fully considers and prevents ESG, emerging risks and other areas, and actively builds a corporate culture of sunshine and integrity.

Sino Biopharm adheres to its internationalization strategy, targeting unmet clinical needs around the world, and promoting the development of more high-quality new drugs and the approval and launch of varieties of new drugs in a synergistic manner between in-house research and development and the introduction of innovations from overseas for the benefit of patients around the world. At the same time, the Group promotes the accessibility of medicines in various aspects. On the one hand, the Group provides patients with quality and affordable medicines through quality improvement and efficiency enhancement; on the other hand, the Group further reduces the burden of patients' medication by developing various public welfare and charitable activities. In the area of talent development, the Group continues to build an excellent work experience, empowering employee development and helping the enterprise and its employees grow together.

In 2023, Sino Biopharm has also been awarded MSCI ESG Class A, CCTV's "Pioneer 100 Chinese ESG Listed Companies", "Forbes 2023 Chinese ESG Innovative Companies", "Top 100 Chinese Overseas Listed Companies" and "Top 100 ESG and Low Carbon Rankings". ESG and Low Carbon Ranking 100" and many other honors.

In the future, Sino Biopharm will adhere to the concept of sustainable development, continuously integrate the ESG concept with the Group's development strategy, improve risk management, promote sound business growth, and create long-term value for shareholders, patients, employees and all sectors of society.

网址：https://www.sinobiopharm.com/news-center/dynamic/24449.html#submenu